Background
RR/MDR-TB among adults with HIV remains a major clinical and public health challenge in high-burden settings (e.g., South Africa). The rollout of bedaquiline- and pretomanid-based regimens (e.g., BPaL/BPaLM) has revolutionized care, delivering unprecedented safety and efficacy. However, baseline and emergent resistance threaten the long-term durability of these regimens, underscoring the need for surveillance and resistance-informed treatment strategies. Data on phenotypic drug susceptibility testing (pDST) for these agents remain scarce, and pretomanid resistance is particularly poorly defined. We assessed baseline and treatment-emergent resistance to bedaquiline and pretomanid among adults with HIV and RR/MDR-TB enrolled in the ADAP-TIV trial in KwaZulu-Natal, South Africa.
Methods
This trial is an ongoing, prospective, adaptive, randomized controlled trial assessing the effectiveness of adherence support strategies on clinical outcomes in adults with HIV and RR/MDR-TB treated with a bedaquiline-containing regimen. Participants with a positive sputum culture for M. tuberculosis from either solid (7H11) or liquid media were included in this analysis. pDST for bedaquiline, pretomanid, linezolid, and moxifloxacin was performed. Resistance was categorized as baseline (present on or before month 2 visit) or emergent (present only in subsequent visits). Critical concentrations were defined as 0.25 μg/mL for both bedaquiline and pretomanid on 7H11 media, 1 μg/mL for linezolid and 2 μg/mL for moxifloxacin, according to established protocols.
Results
195 individuals were evaluated, 129 (66.8%) tested culture-positive on their sputum samples. Among individuals with RR (110/129), baseline phenotypic resistance to bedaquiline and pretomanid was observed in 6 (5.5%) and 3 (2.7%) of individuals, respectively. Emergent resistance to bedaquiline and pretomanid was noted in 3 (2.7%) and 1 (0.9%) individuals, respectively. Additionally, 2 (1.8%) individuals exhibited baseline resistance to moxifloxacin, and 1 (0.9%) showed emergent resistance. There was no observed resistance to linezolid.
Conclusions
Phenotypic resistance to bedaquiline and pretomanid is not uncommon, with baseline resistance as high as 5.5% among patients with RR-TB and HIV in this high burden setting. The emergence of resistance during treatment underscores the need for accessible, rapid pDST to guide clinical decision-making, inform public health strategies, and support stewardship to preserve the durability of these regimens.